AlphAIAlphAI — Financial news for AI agents
investorideas.comOCT 292 min read$BHC

Bausch Health Companies (NYSE:BHC)(TSX:BHC) Soars on Solid Third Quarter

Bausch Health (NYSE:BHC, TSX:BHC) shares rose over 23% after reporting strong Q3 2026 results, including 14 straight quarters of revenue and Adjusted EBITDA growth. The company raised full-year 2026 guidance and announced a $50M share repurchase program. Q3 revenues were $2.94B, up 10% year-over-year, with Adjusted EBITDA of $1.3B, up 32%.

Original reporting
investorideas.com
Published Oct 29, 2026, 3:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 7:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bausch Health Companies (NYSE:BHC)(TSX:BHC) Soars on Solid Third Quarter — source image
Source · investorideas.com
Decision brief

The 30-second read

$BHCBullishHigh
01

Why it matters

The earnings beat and guidance raise triggered a 23% intraday rally, indicating strong investor demand.

02

Market read

The earnings surprise and guidance lift make BHC a top mover, with potential spill‑over to health‑care peers.

03

What to watch

Potential headwinds from regulatory scrutiny of Bausch + Lomb products and currency fluctuations.

Relevance 8/10Novelty 8/10Timing: today

Background

Bausch Health Companies Inc. (NYSE:BHC, TSX:BHC) announced its Q3 2026 earnings, raising full‑year guidance and authorizing a $50 million share repurchase.

Company-level read

Ticker impact

$BHCBullishHigh confidence
Context

Bausch Health reported Q3 2026 results with 10% revenue growth, $1.3B adjusted EBITDA and raised full‑year guidance, driving a 23% stock surge.

Expected impact

upward pressure as investors price in higher earnings and the new $50M buyback.

Evidence & confidence

Revenue and EBITDA beat expectations, guidance raised, and a share repurchase program all support a bullish outlook.

Market effects

Sector

Positive for the broader pharma/healthcare sector as the beat may lift peers.

Regional

Boosts Canadian market sentiment, especially TSX health‑care stocks.

Global

Limited to healthcare investors; no macro impact.

Counterpoint

What could challenge this read

If guidance proves unsustainable, the stock could face a pull‑back after the initial rally.

Key entities

  • Executive
    Thomas J. Appio

    CEO of Bausch Health who commented on the results.

Read at source← All news

StoryBausch Health posts Q3 2026 earnings beat, raises full‑year guidance and launches $50 M buyback

Also covered by

4 outlets

Related articles

OCT 29
$BHCMedAI 8/10

Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone

Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.

finance.yahoo.com5 min
OCT 29
$BHCHighAI 8/10

Bausch Health Companies Inc (BHC) Q3 2026 Earnings Call Highlights: Adjusted EBITDA Tops

Bausch Health (BHC) reported Q3 2026 earnings, raising full-year guidance. Adjusted EBITDA exceeded $1B. CFO JJ Sharon noted a $100M+ impact from Xifaxan price adjustments. CEO Thomas Appio discussed Solta's growth and regulatory timelines. Salix revenue rose 16% to $831M, driven by Xifaxan. The company reduced debt by $521M and announced a $50M share repurchase program.

finance.yahoo.com2 min
OCT 29
$BHCHighAI 8/10

Bausch Health (BHC) Q3 2026 Earnings Call Transcript

Bausch Health (BHC) reported Q3 2026 earnings, marking 4 consecutive quarters of year-over-year revenue and adjusted EBITDA growth. The company exceeded $1 billion in quarterly adjusted EBITDA and reduced net debt by over $500 million. Salix revenue increased 16%, while international business grew mid-single-digit. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow from operations.

finance.yahoo.com2 min